Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
31,877,280
-
Shares change
-
+749,165
-
Total reported value, excl. options
-
$641,628,318
-
Value change
-
+$12,346,028
-
Put/Call ratio
-
54%
-
Number of buys
-
41
-
Number of sells
-
48
-
Price
-
$20.13
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2018
As of 31 Dec 2018 Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) had 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 31,877,280 shares of stock of the company.
Largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, JPMORGAN CHASE & CO, BlackRock Inc., FRANKLIN RESOURCES INC, Bank of New York Mellon Corp, ArrowMark Colorado Holdings LLC, Vanguard Group Inc, ALLIANCEBERNSTEIN L.P., NovaQuest Capital Management, L.L.C., and Capital World Investors.
This table shows 97 institutional shareholders of the security as of 31 Dec 2018.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.